1. A retrofit luminaire assembly adapted for downward illumination and having a housing with inwardly-directed ledges near the lower edges of the housing, comprising:
at least two support brackets secured to at least one of the ledges;
a face plate removably secured to the brackets on the lower side of the housing, the face plate adapted to hold lighting fixture components; and
first and second hanging tethers each attached at its proximal end to a separate one of the support brackets along one side of the housing, the first and second tethers being secured at their distal ends to opposite ends of one side of the faceplate,
wherein when the face plate is removed from the brackets, the face plate hangs freely held by the tethers to allow free access to the inside of the luminaire.
2. A method of installing a retrofit luminaire assembly adapted for downward illumination and having a housing with inwardly-directed ledges near the lower edges of the housing, the method comprising the steps of:
providing at least two support brackets;
securing the two support brackets to at least one ledge;
providing a face plate adapted to hold lighting fixture components;
providing first and second hanging tethers each attached at its proximal end to a separate one of the support brackets along one side of the housing, the first and second tethers being secured at their distal ends to opposite ends of one side of the faceplate; and
securing the face plate to the brackets with the tethers such that the face plate hangs freely without further support during installation.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A process for preparing a compound of formula (I):
or a pharmaceutically acceptable salt thereof, the process comprising:
(a) reacting a compound of formula (II):
wherein:
each R1 is independently H or a protecting group,
with a compound of formula (III):
to produce a compound of formula (IV):
(b) selectively protecting the compound of formula (IV) to prepare a compound of formula (V):
(c) phosphorylating the compound of formula (V) to prepare a compound of formula (VI):
(d) oxidizing the compound of formula (VI) to prepare a compound of formula (VII):
and (e) deprotecting the compound of formula (VII) to prepare the compound of formula (I).
2. The process of claim 1, wherein the pharmaceutically acceptable salt is an HCl salt.
3. The process of claim 1, wherein the compound of formula (II) is:
4. The process of claim 1, wherein the compound of formula (III) is a protected or unprotected galactose, mannose, glucose, or gulose.
5. The process of claim 1, wherein the compound of formula (III) is:
6. The process of claim 1, wherein two adjacent R1 groups come together to form an isopropylidine acetal or benzylidine acetal moiety.
7. The process of claim 1, wherein step (a) comprises reacting the compound of formula (II) and the compound of formula (III) in the presence of a hydrazine.
8. The process of claim 7, wherein the hydrazine is selected from the group consisting of phenylhydrazines and alkylhydrazines.
9. The process of claim 8, wherein the hydrazine is phenylhydrazine.
10. The process of claim 1, wherein the phosphorylation of step (c) comprises reacting the compound of formula (V) with a P(V) phosphorylating agent.
11. The process of claim 10, wherein the P(V) phosphorylating agent is selected from the group consisting of: POCl3; H3PO4; PO(OBn)xCl3-x; Cl3CCH2OP(O)Cl2; and (BnO)2P(O)OP(O)(OBn)2.
12. The process of claim 10, wherein the P(V) phosphorylating agent is POCl3.
13. The process of claim 1, wherein the phosphorylation of step (c) comprises reacting the compound of formula (V) with a P(III) phosphitylating agent.
14. The process of claim 13, wherein the P(III) phosphitylating agent is selected from the group consisting of: P(OCH2CH2CN)2Cl; P(OCH2CH2CN)(NPr2-i)Cl; and cyanoethyl-O\u2014PN(i-Pr)2)2.
15. The process of claim 13, wherein step (c) further comprises oxidizing the resulting phosphite to prepare the phosphate of compound (VI).
16. The process of claim 1, wherein step (d) comprises reacting the compound of formula (VI) with an oxidizing agent selected from the group consisting of: RuO4; Dess-Martin; DMSOtriflic anhydride; and PDC.
17. The process of claim 1, wherein the deprotection of the compound of formula (VII) is performed under anaerobic conditions.
18. The process of claim 1, wherein the compound of formula (IV) is:
19. The process of claim 1, wherein the compound of formula (V) is:
20. The process of claim 1, wherein the compound formula (VI) is:
21. The process of claim 1, wherein the compound of formula (VII) is:
22. The process of claim 1, wherein the process further comprises formulating the compound of formula (I) as a pharmaceutical composition.
23. A compound of formula (IV):
or a pharmaceutically acceptable salt form thereof, wherein:
each R1 is independently H or a protecting group.
24. A compound of formula (V):
or a pharmaceutically acceptable salt form thereof, wherein:
each R1 is independently H or a protecting group.
25. A compound of formula (VI):
or a pharmaceutically acceptable salt form thereof, wherein:
each R1 is independently H or a protecting group, and at least R1 is a protecting group.
26. A compound of formula (VII):
or a pharmaceutically acceptable salt form thereof, wherein:
each R1 is independently H or a protecting group; and at least one R1 is a protecting group.
27. A process for preparing a compound of formula (XIII):
or a pharmaceutically acceptable salt form thereof, the process comprising:
(a) reacting a compound of formula (II):
with a compound of formula (III):
to produce a compound of formula (IV):
wherein:
each R1 is independently H or a protecting group;
(b) selectively protecting the compound of formula (IV) to prepare a compound of formula (V):
(c) phosphorylating the compound of formula (V) to prepare a compound of formula (VI):
(d) oxidizing the compound of formula (VI) to prepare a compound of formula (XIV):
and (e) deprotecting the compound of formula (XIV) to prepare the compound of formula (XIII).
28. The process of claim 27, wherein the pharmaceutically acceptable salt is an HCl salt.
29. The process of claim 27, wherein the compound of formula (II) is:
30. The process of claim 27, wherein the compound of formula (III) is a protected or unprotected galactose, mannose, glucose, or gulose.
31. The process of claim 27, wherein the compound of formula (III) is:
32. The process of claim 27, wherein two adjacent R1 groups come together to form an isopropylidine acetal or benzylidine acetal moiety.
33. The process of claim 27, wherein step (a) comprises reacting the compound of formula (II) and the compound of formula (III) in the presence of a hydrazine.
34. The process of claim 33, wherein the hydrazine is selected from the group consisting of phenylhydrazines and alkylhdrazines.
35. The process of claim 34, wherein the hydrazine is phenylhydrazine.
36. The process of claim 27, wherein the phosphorylation of step (c) comprises reacting the compound of formula (V) with a P(V) phosphorylating agent.
37. The process of claim 36, wherein the P(V) phosphorylating agent is selected from the group consisting of: POCl3; H3PO4; PO(OBn)xCl3-x; Cl3CCH2OP(O)Cl2; and (BnO)2P(O)OP(O)(OBn)2.
38. The process of claim 37, wherein the P(V) phosphorylating agent is POCl3.
39. The process of claim 27, wherein the phosphorylation of step (c) comprises reacting the compound of formula (V) with a P(III) phosphitylating agent.
40. The process of claim 39, wherein the P(III) phosphitylating agent is selected from the group consisting of: P(OCH2CH2CN)2Cl; P(OCH2CH2CN)(NPr2-i)Cl; and cyanoethyl-O\u2014PN(i-Pr)2)2.
41. The process of claim 39, wherein step (c) further comprises oxidizing the resulting phosphite to prepare the phosphate of compound (VI).
42. The process of claim 27, wherein step (d) comprises reacting the compound of formula (VI) with an oxidizing agent selected from the group consisting of: Ru04; Dess-Martin; DMSOtriflic anhydride; and PDC.
43. The process of claim 27, wherein the deprotection of the compound of formula (XIV) is performed under anaerobic conditions.
44. The process of claim 27, wherein the compound of formula (IV) is:
45. The process of claim 27, wherein the compound of formula (V) is:
46. The process of claim 27, wherein the compound formula (VI) is:
47. The process of claim 27, wherein the compound of formula (XIV) is:
48. The process of claim 27, wherein the process further comprises formulating the compound of formula (XIII) as a pharmaceutical composition.